MedTech Localization Has Zero Room for Error

When the Reader Is a Surgeon Mid-Procedure, Wrong Words Kill

Cordis Corporation sells cardiovascular devices in more than 70 countries. Their marketing leader Terrence Wiggins spent two decades orchestrating over 40 product launches across 135 markets at companies like Stryker, Terumo, and Cook Medical. In a recent podcast episode, he made a point that every healthcare localization team should pin to their wall: in MedTech, your audience is a physician choosing a device mid-procedure, and the message has to be exactly right every single time.

That is not a metaphor. It is a job description for your translation vendor.

The MedTech sector is one of the clearest examples of why generic, lowest-cost translation is a liability rather than a savings. Regulatory bodies in the US, EU, Japan, and elsewhere require device labeling, instructions for use, and clinical claims to be accurate, consistent, and traceable. A term that is slightly off in one language can constitute a false claim. A dosage instruction that reads ambiguously in translation can contribute to patient harm. The stakes compress every margin for error out of existence.

Regulatory Complexity Does Not Stop at the Big Markets

Most healthcare organizations obsess over their FDA submissions, their CE marking documentation, their Japanese PMDA filings. Those are the obvious checkpoints. What gets less attention is the tail end of the language list — the markets where the patient population is small, the language is rarely supported by major translation engines, and the regulatory pathway is less familiar.

This is where coherent global messaging actually breaks down.

Wiggins described the challenge of holding a single brand voice together across wildly different regulatory and language environments. That challenge is manageable in German, French, or Mandarin, where mature localization infrastructure exists. It becomes genuinely difficult in languages with limited digital resources, few qualified translators, and no established machine translation pipeline.

For US-based healthcare systems — not MedTech manufacturers, but hospitals, Federally Qualified Health Centers, and public health agencies — the problem is closer to home than most administrators realize.

The Pacific Island Patient Nobody Planned For

Here is a scenario that plays out regularly in US healthcare, and that no major localization platform is built to solve.

A hospital in Hawaii or Guam treats a patient who speaks Chuukese as their primary language. Chuuk is a group of islands in Micronesia. Chuukese speakers in the United States number in the tens of thousands, concentrated in Hawaii, Guam, and increasingly in communities in Arkansas, Oregon, and Washington state. Their presence is a direct result of the Compact of Free Association, which gives Micronesian citizens the right to live and work in the US.

Those patients need informed consent documents, discharge instructions, and medication guides in a language that major translation providers routinely list as unavailable. The hospital's TMS does not have a Chuukese workflow. The language access coordinator has no vendor to call. And the patient — who may be presenting with a cardiovascular condition requiring a device very much like the ones Cordis makes — cannot fully understand what is being done to them.

Pohnpeian presents the same gap. So does Marshallese, though Marshallese has slightly more translation infrastructure than the other two.

The MedTech localization challenge Wiggins describes — zero room for error, coherent messaging, regulatory accountability — does not get easier when you move from German to Chuukese. It gets harder by an order of magnitude.

What the MedTech Standard Actually Requires

Wiggins framed his work around a core idea: the value proposition has to travel intact across every market. Features and benefits are not enough. The story has to hold together. That requires more than word-for-word translation. It requires translators who understand the clinical context, the regulatory constraints, and the cultural expectations of the target audience.

For rare Pacific languages, that means working with human translators who are native speakers with healthcare experience — not post-editors cleaning up machine translation output, because there is no reliable MT engine for Chuukese or Pohnpeian. The translator has to carry the full weight of clinical accuracy without a machine assist.

Here is a practical comparison of what localization looks like across the spectrum:

For languages in the bottom three rows, every translated document is essentially a first-principles exercise. The translator cannot rely on standardized glossaries or vetted style guides. Quality assurance depends entirely on the rigor of the review process and the subject-matter expertise of the people involved.

The Lesson Healthcare Organizations Should Take From MedTech

MedTech companies like Cordis operate under enforcement pressure that forces discipline. They document translation decisions, maintain version control across language variants, and treat localization as a compliance function rather than a communications afterthought.

Most US hospitals and school districts do not work that way. Language access is often reactive — a patient shows up, a need is identified, someone scrambles. That scramble almost always fails for Chuukese and Pohnpeian speakers, because the infrastructure is not in place before the need arrives.

The practical takeaway is this: if your organization serves any population in Hawaii, Guam, or a growing mainland Micronesian community, build your rare-language translation relationships before a compliance audit or a patient harm event forces the issue. Identify a vendor with verified Chuukese and Pohnpeian capacity. Establish glossaries for your most common clinical contexts. Create a review workflow that does not depend on finding a qualified speaker at 11pm on a Tuesday.

Wiggins put it plainly: at the end of the day, it is about the patient. That is as true for a Chuukese-speaking patient in Honolulu as it is for a German-speaking patient in Frankfurt. The standard does not change because the language is rare.

If you need to assess your current rare-language coverage, TXLOC is happy to walk through your specific language list with you.